Core Insights - Daré Bioscience, Inc. has received a $6 million non-dilutive funding installment, increasing total funding to approximately $37.8 million out of a potential $49 million for the development of DARE-LARC1, a contraception-focused application of its intelligent drug delivery system [1][10] - DARE-LARC1 is a preclinical-stage long-acting reversible contraceptive utilizing a programmable drug delivery device to administer levonorgestrel, with broader applications in various chronic conditions [2][6] - The DARE-IDDS platform, originally developed at MIT, has been enhanced by Daré to improve its functionality and is capable of delivering multiple doses over extended periods without the need for recharging or surgical replacement [3][4] Funding and Development - The recent funding milestone will support the advancement of DARE-LARC1 and the development of a versatile drug delivery platform across high-value therapeutic areas [3][10] - Daré is eligible for additional non-dilutive funding of up to approximately $11.2 million, contingent on achieving specified technical milestones [10] Market Potential - The DARE-IDDS platform has potential applications beyond reproductive health, including obesity, diabetes, and other chronic conditions, which could significantly improve patient adherence and reduce healthcare costs [6][7] - The platform's features include precision dosing, extended duration of action, and remote programmability, making it suitable for various therapeutic areas [9] Strategic Partnerships - Daré is actively exploring strategic partnerships to expand the evaluation of the DARE-IDDS platform into additional therapeutic categories [2][10] - The company aims to leverage its innovative technology to address unmet needs in women's health and enhance treatment options [11]

Core Viewpoint - ASP Isotopes Inc. has announced the overwhelming approval of its acquisition of Renergen Limited by shareholders, with 99.80% voting in favor of the scheme [1][2]. Group 1: Acquisition Details - The acquisition is subject to regulatory approvals and third-party consents, expected to be fulfilled by September 30, 2025, with the scheme anticipated to become effective in Q3 2025 [2]. - Renergen focuses on the production of liquefied helium and liquefied natural gas, with U.S. government funding due to helium's strategic importance [3]. Group 2: Strategic Goals - The merger aims to create a global leader in critical materials production, including electronic gases and isotopically enriched gases, with significant synergies expected from 2026 [3]. - The combined entity targets generating over $300 million in EBITDA by 2030, driven by isotope, helium, and LNG sales in the South African energy market [4]. Group 3: Industry Impact - The merger is expected to enhance supply chain stability, particularly benefiting the semiconductor and electronics industries, positioning the group favorably for the global AI revolution [5]. - Both isotopes and helium are recognized as critically important materials by Western governments, emphasizing the strategic value of the combined company [6]. Group 4: Technological Focus - ASP Isotopes employs proprietary Aerodynamic Separation Process technology for isotope production, with plans to enrich isotopes for healthcare and nuclear energy sectors [6][7]. - There is a growing demand for various isotopes for applications in quantum computing and green energy, indicating a robust market potential for the combined company [7].

Core Insights - Mixed Martial Arts Group Limited (MMA) has expanded its strategic technology partnership with UFC Gym Group, selecting BJJLink.com as the official gym management software for new UFC GYM BJJ franchise studios [2][3] - This partnership aligns with UFC GYM's global expansion and the growth of its Brazilian Jiu-Jitsu (BJJ) program, supported by the launch of UFC's new BJJ live event series [3][6] - The BJJLink platform will serve as the operational backbone for UFC GYM's BJJ studios, providing franchisees with tools to streamline operations and enhance member experience [4][5] Company Developments - UFC GYM plans to open over 45 new gyms in 2025, with BJJ-first models ranging from 2,000 to 5,000 square feet, featuring advanced facilities [5][6] - The expanded agreement includes access to BJJLink Admin+, which simplifies operations through features like automated billing, class scheduling, and centralized reporting [4][7] - The partnership aims to enhance technical scalability and operational consistency for UFC GYM's ambitious rollout of new BJJ studios globally [5][6] Industry Trends - The demand for BJJLink has increased among franchise operators seeking streamlined onboarding and revenue analytics [8] - MMA.INC is expanding BJJLink into Latin America and has formed a partnership with Gracie Allegiant HQ and Brazilian Jiu-Jitsu legend Clark Gracie [9] - The integration of digital tools in martial arts training is seen as a key trend, with a focus on both physical and digital training environments [6]

KALMAR CORPORATION, PRESS RELEASE, 11 JULY 2025 AT 15:00 PM (EEST) Kalmar’s January-June 2025 half-year financial report to be published on Friday, 25 July 2025 Kalmar Corporation will publish its January-June 2025 half-year financial report on 25 July 2025 at approximately 9:00 a.m. EEST. The report will be available at www.kalmarglobal.com after publication. A live international telephone conference for analysts, investors and media will be arranged on the publishing day at 10:00 a.m. EEST. The event will ...

Group 1 - Crinetics Pharmaceuticals, Inc. will report its second quarter 2025 financial results on August 7, 2025, after market close [1] - A conference call will be held at 4:30 p.m. ET on the same day to discuss the financial results and provide a business update [1][2] - The conference call can be accessed via dial-in numbers or a live webcast, with a recommendation to connect 15 minutes prior to the start [2] Group 2 - Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on developing novel therapeutics for endocrine diseases and related tumors [4] - The lead development candidate, PALSONIFY (paltusotine), is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors [4] - Other drug candidates include Atumelnant, which is in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, with all candidates being orally delivered small molecules [4]

Core Insights - Cerevance is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases and obesity, with presentations scheduled at the Alzheimer's Association International Conference (AAIC) 2025 [1] Group 1: Upcoming Presentations - Cerevance will present a Phase 1 study on CVN293, an investigational inhibitor targeting NLRP3-mediated neuroinflammation, on July 28, 2025 [2] - Another presentation will focus on the NETSseq platform, revealing insights into astrocyte function in Alzheimer's disease, scheduled for July 30, 2025 [2] Group 2: NETSseq Platform - The NETSseq platform allows for the identification of subtle molecular changes driving disease progression by analyzing brain tissue from over 20,000 donors aged 8 to 104 [3] - This platform aids in identifying low-level expressed targets and rare cell types, enhancing the understanding of neurodegenerative diseases [3] Group 3: CVN293 Overview - CVN293 is a selective oral inhibitor of KCNK13, aimed at reducing neuroinflammation and potentially modifying disease progression in neurodegenerative disorders [4] - The mechanism of CVN293 may also provide therapeutic benefits for obesity, identified through the NETSseq platform [4] Group 4: Company Pipeline - Cerevance's lead investigational treatment, solengepras, is in Phase 3 development for Parkinson's disease, while CVN766 targets binge eating disorder and schizophrenia [5] - CVN293 represents a novel intervention point for both neurodegenerative disorders and obesity [5]

The leading facility, engineering and infrastructure provider recognized for sales culture excellenceNEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- ABM (NYSE: ABM), a leading provider of integrated facility, engineering, and infrastructure solutions announced today it has been included on Selling Power Magazine’s list of 60 Best Companies to Sell For 2025. This is the fourth consecutive year ABM has earned the recognition. More than 200 companies were analyzed across key categories, including: Company Overview ...

PHILADELPHIA, July 11, 2025 (GLOBE NEWSWIRE) -- Enviri Corporation (NYSE: NVRI) today announced that it will issue its second quarter 2025 earnings results on Tuesday, August 5, 2025 prior to NYSE market open. The Company will also host its quarterly conference call and webcast that morning beginning at 9:00 a.m. ET. Those who wish to listen to the conference call webcast should visit the Investor Relations section of the Company’s website at www.enviri.com. The live call also can be accessed using the belo ...

BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” the “Company”) today announced that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co. (“Glass Lewis”) recommend that stockholders vote FOR the issuance of shares in connection with the previously disclosed proposed merger with Inmagene Biopharmaceuticals (“Inmagene”) at Ikena’s upcoming Annual Meeting of Stockholders on July 15, 2025. ISS and Glass Lewis are leading U.S. institutional voting advisory ...

Core Insights - Evaxion A/S has finalized an agreement with the European Investment Bank (EIB) to convert €3.5 million of its €7 million loan into equity, enhancing its capital structure and financial flexibility [1][2][6] Group 1: Financial Impact - The conversion involves EIB purchasing ordinary Evaxion warrants at a price of $4.87, which represents a premium of 89% over the share price at market close yesterday [2][6] - This agreement immediately increases Evaxion's equity by $4.1 million (€3.5 million), while also substantially reducing overall liabilities and simplifying the balance sheet [2][6] Group 2: Management Commentary - The CFO of Evaxion, Thomas F. Schmidt, expressed satisfaction with the favorable terms of the agreement, highlighting its importance for cash flow and financial management [3]